Kadcyla®: HCP Educational Information

EU Healthcare Professional Information

April, 2020

WARNING:
Risk of confusion between Kadcyla (trastuzumab emtansine) and Herceptin (trastuzumab)
During the prescription, preparation and administration processes
Confusion can lead to overdose, undertreating and/or toxicity

Kadcyla (trastuzumab emtansine):

Kadcyla (trastuzumab emtansine) is an antibody–drug conjugate containing humanised anti-HER2 IgG1 antibody trastuzumab linked to DM1, a microtubule-inhibitory maytansinoid. **Emtansine refers to the combination of the linker and DM1.**

Metastatic Breast Cancer (MBC)

Kadcyla, as a single agent, is indicated for the treatment of adult patients with **HER2-positive, unresectable, locally advanced or metastatic breast cancer** who previously received trastuzumab and a taxane, separately or in combination.

Patients should have either:

- Received prior therapy for locally advanced or metastatic disease, or
- Developed disease recurrence during or within 6 months of completing adjuvant therapy.

Important information:

- Kadcyla (trastuzumab emtansine) and Herceptin (trastuzumab) are two ***different*** products with ***different*** active substances
- Trastuzumab emtansine and trastuzumab are not interchangeable
- Kadcyla (**trastuzumab emtansine)** is ***not*** a generic version or biosimilar of Herceptin-(trastuzumab)
- Do not administer trastuzumab emtansine in combination with trastuzumab or with a chemotherapy
- Do not administer trastuzumab emtansine at doses greater than 3.6 mg/kg q3w

Trademark	Herceptin trastuzumab	Herceptin SC trastuzumab subcutaneous	Kadcyla trastuzumab emtansine
Indication	HER2-positive BC HER2-positive MGC	HER2-positive BC	**HER2-positive BC**
INN	trastuzumab	trastuzumab	**trastuzumab emtansine**
Dose (q3w)	8 mg/kg LD - 6 mg/kg	Fixed dose of 600 mg	**3.6 mg/kg**
Form	Powder	Solution	**Powder**
Vial content	150 mg	600 mg	**100 mg and 160 mg**
Vial size	15 ml	5 ml	**15 ml and 20 ml**

BC, breast cancer; LD, loading dose; MGC, metastatic gastric or gastro-oesophageal junction adenocarcinoma.
Please be aware that biosimilars of Herceptin (trastuzumab) and other drugs containing trastuzumab may also be available for administration by IV infusion.

Avoiding errors: Physicians/prescription phase

Due to the similar INN (trastuzumab vs **trastuzumab emtansine**) errors can occur when prescribing.

Electronic systems: Potential areas of confusion







Alphabetical name sorting	Name truncation & Limited text field
Trastuzumab and **trastuzumab emtansine** may be positioned one after the other	If the system only displays part of the medication name in its drop-down menu or text window (e.g. trastuzumab and trastuzumab emtansine)

Written prescriptions: Potential areas of confusion

Both Kadcyla and **trastuzumab emtansine** should always be used when prescribing.

Example	Do not truncate either name
Kadcyla (trastuzumab emtansine) Trastuzumab emtansine (Kadcyla)	Kadcyla (trastuzumab e) Kadcyla (trastuzumab) Trastuzumab e

Mitigation measures

- Prescribers must familiarise themselves with the Kadcyla SmPC
- Refer to Kadcyla and **trastuzumab emtansine** when discussing the drug with the patient
- Electronic systems
  - Check correct medication before clicking
  - Always select the correct medication in the electronic medical record
  - Ensure the medication prescribed is Kadcyla, **trastuzumab emtansine**, and not trastuzumab
  - Request use of brand names, where possible
- Written prescriptions
  - Ensure that both Kadcyla and **trastuzumab emtansine** are written on the prescription and in the patient notes
  - Do not abbreviate, truncate or omit any name
- Ensure the correct medication is clearly recorded in the patient history

Avoiding errors: Pharmacists/preparation phase

Trademark		Herceptin® SC trastuzumab subcutaneous	Kadcyla trastuzumab emtansine	
Content	440 mg	600 mg	100 mg	160 mg
Carton image & colours				
Label colours				
Cap colour				
Distinctive colours	Dark orange/ green	Dark orange/ light blue	Yellow/ white	Yellow/ purple

Please be aware that biosimilars of Herceptin (trastuzumab) and other drugs containing trastuzumab may also be available for administration by IV infusion

Potential mitigation measures:

- Pharmacists must familiarise themselves with the Kadcyla SmPC
- Check that protocols to avoid medication errors are in place at the hospital/site and that they are followed
- Be aware when reading prescriptions that there are three types of medication with a similar INN (trastuzumab, trastuzumab SC and **trastuzumab emtansine**)
- Double check the intended medication is Kadcyla, **trastuzumab emtansine,** and that both are entered in the prescription and/or medical history
- In case of any doubt, consult with the treating physician
- Familiarise yourself with the different cartons, labels and cap colours to select the correct carton
- Ensure the correct medication is ordered from the wholesaler and that the correct medication is received in the pharmacy
- Store Kadcyla (trastuzuamb emtansine) in a different place in the fridge to trastuzumab IV and Herceptin SC

- Nurses must familiarise themselves with the Kadcyla SmPC. Ensure that protocols to avoid medication errors are in place at the hospital/site and that they are followed
- Check both the prescription and patient notes to ensure that Kadcyla and **trastuzumab emtansine** have been recorded as the prescribed medication
- On receipt of the infusion bag, check the label on the infusion bag against the prescription **and** patient notes
- Consider using a two nurse double-checking system prior to infusion to ensure that the appropriate product and dosage is administered
- Refer to both Kadcyla and **trastuzumab emtansine** when discussing the drug with the patient
- Do not administer Kadcyla (trastuzumab emtansine) at doses greater than 3.6 mg/kg q3w
- Familiarise yourself with the Kadcyla (trastuzumab emtansine) dose modification for toxicities

Gayane Ghazaryan 10.04.20

Medical Manager of Hoffmann La Roche Products in Armenia

Nune Karapetyan 10.04.2020

Commercial Lead of Hoffmann La Roche Products in Armenia